<?xml version="1.0" encoding="UTF-8"?>
<p>Lassa virus (LASV) is the causative agent of Lassa fever, which is estimated to cause 100,000 to 300,000 infections annually in west Africa, with approximately 5,000 deaths (
 <xref rid="B1" ref-type="bibr">1</xref>). Nosocomial epidemics of Lassa fever are associated with higher case fatality rates up to 36 to 65% (
 <xref rid="B2" ref-type="bibr">2</xref>, 
 <xref rid="B3" ref-type="bibr">3</xref>). A seasonal outbreak of Lassa fever occurred in Nigeria in 2018 and led to more than 100 deaths, reemphasizing the threat of LASV on public health (
 <xref rid="B4" ref-type="bibr">4</xref>). There is no U.S Food and Drug Administration-approved vaccine for LASV, and the only treatment option for Lassa fever is the nucleoside analog drug ribavirin, which is most effective when given in the early stage of the disease (
 <xref rid="B5" ref-type="bibr">5</xref>). Due to its high morbidity and mortality rates, LASV is classified as a biosafety level 4 (BSL-4) agent (
 <xref rid="B6" ref-type="bibr">6</xref>) and a category A priority pathogen (
 <xref rid="B7" ref-type="bibr">7</xref>).
</p>
